Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 3/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10440258 | 0.83 | PDE4B (0.42) | PDE4BKMT2APDE4D | |
| SCHEMBL8067073 | 0.82 | PDE4B (0.50) | PDE4BCHRM3TNIKROCK2GRM2 | |
| SCHEMBL3792872 | 0.82 | PDE4B (0.49) | PDE4BTNIKKMT2APDE4D | |
| SCHEMBL13578412 | 0.77 | PDE4B (0.41) | PDE4BHTR7PDE4D | |
| SCHEMBL13578406 | 0.76 | CD274 (0.51) | — | |
| SCHEMBL13578405 | 0.76 | CD274 (0.51) | — | |
| SCHEMBL13578404 | 0.76 | HTR7 (0.47) | PDE4BHTR7 | |
| SCHEMBL10440089 | 0.76 | PDE4D (0.40) | PDE4BHTR7PDE4D | |
| SCHEMBL4973888 | 0.75 | TNIK (0.47) | PDE4BTNIKROCK2ROCK1KMT2A | |
| SCHEMBL13578408 | 0.74 | PDE4D (0.47) | PDE4BHTR7PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324569-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | PDE4B 2/4885CHRM3 2142/4885TNIK 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.